Bioxyne Limited · ASX:BXN
Bioxyne — NWR Virtual Healthcare Conference 2026
12 slides from Bioxyne's conference presentation, Mar 25, 2026
Slide 1: NWR Virtual Healthcare Conference
For personal use only NWR Virtual Healthcare Conference ASX:BXN 25 March 2026
Slide 2: Redefining Medicine
Redefining Medicine World’s Fastest Growing Pharmaceutical Manufacturer of For personal use only Cannabis | Psilocybin | MDMA Innovative medicines for patients with unmet clinical needs $4 BILLION+ / YEAR DEMAND REGULATORY BARRIERS Mental health + chronic conditions = growing unmet Highly regulated
Slide 3: H1 FY2026 Overview
H1 FY2026 Overview Record half driven by sustained demand for GMP-manufactured medicinal cannabis, MDMA and psilocybin products For personal use only $31.3m $7.3m $8.3m Revenue NPAT Adjusted EBITDA +149% pcp +121% pcp +137% pcp $7.6m Cash on Hand $20m Net Assets +$8m Revenue Per month FY26 Adjusted
Slide 4: Pharmaceutical Supply Chain – Doing what others don't / cannot do
Pharmaceutical Supply Chain –Doing what others don’t / cannot do BIOXYNE For personal use only Raw Active PHARMACEAUTICAL WHOLESALE / Pharmacy / Prescribing Patient Materials Pharmaceutical MANUFACTURING DISTRIBUTION Dispensary Physician (Cultivators of Ingredients (API) Mushrooms, Cannabis) Supplie
Slide 5: Bioxyne - market leading manufacturer with >$250m/year capacity
Bioxyne - market leading manufacturer with >$250m /year capacity TGA GMP LICENCED PHARMACEUTICAL MANUFACTURER DISTRIBUTING GLOBALLY For personal use only PHARMACEAUTICAL Wholesale MANUFACTURER Distributor Integrated Pharmaceutical Manufacturing Platform •Licensed by TGA, QLD Health and ODC TGA Licen
Slide 6: Australia: Regulatory Tailwinds Driving Accelerated Growth
Australia: Regulatory Tailwinds Driving Accelerated Growth 01 02 For personal use only Local demand for Cannabis medication set to explode Our Capacity Advantage • Legislative reform to Driving laws: TAS, NT, VIC trials underway; • AU Current capacity: 5.2 million medicines (enough to more than NSW
Slide 7: Our Growth Drivers & Operational Execution
Our Growth Drivers & Operational Execution GROWTH DRIVERS EXECUTION & PROOF For personal use only Growing patient demand and regulatory progress Capacity expansion 4 new clean rooms | +150% processing capacity International expansion – UK, Germany, Europe Improved unit economics New contract wins wi
Slide 8: Global Expansion
Global Expansion Replicating Proven Capability For personal use only United Kingdom Germany & Europe LATAM & Beyond UK Market EU Market Entry Central America £850k | A$1.7m secured Adrex Pharma — $6 initial orders completed ~A$1m potential annual revenue October 2025 thru February 2026 £850k (A$1.7m
Slide 9: Corporate Structure
Corporate Structure CAPITAL STRUCTURE SHAREHOLDER BREAKDOWN For personal use only Share price $0.052 Market capitalisation $116.5m Directors Other 52-week high $0.060 31% 52-week low $0.019 BXN Share Price Performance – 12 Months (Feb 2025 – Feb 2026) 69% $0.06 60m Top 20 Other 30% $0.04 40m 70% $0.
Slide 10: Disclaimer
Disclaimer This presentation (Presentation) has been prepared by Bioxyne Limited ABN 97 084 464 193 (Bioxyne or the Company). The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The information in this presentation is subjec
Slide 11: For personal use only
For personal use only ASX: BXN | HEALTHCARE VIRTUAL CONFERENCE MARCH 2026
Slide 12: For personal use only
For personal use only Sam Watson Jason Hine Melissa Tempra Managing Director Executive Director/Chief Operations Officer Media and Investor Relations sam@breathelifesciences.com jason@breathelifesciences.com melissa@nwrcommunications.com.au